SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Sidney Reilly who wrote (2438)8/25/1999 1:10:00 AM
From: Walter Morton  Respond to of 2742
 
CIST may not be bought. They may just get another agreement like the one with PMC.

If CIST is acquired, the stock will rise to the expected purchase price.

If CIST simply gets another $30 million royalty agreement, the stock will go back to $.25



To: Sidney Reilly who wrote (2438)8/28/1999 4:29:00 AM
From: Walter Morton  Respond to of 2742
 
I wonder how much of these increase can be attributed to CIST's product line?

Message 11093067



To: Sidney Reilly who wrote (2438)9/28/1999 6:05:00 PM
From: Walter Morton  Read Replies (1) | Respond to of 2742
 
10-K has been filed with the SEC:

Summary:
biz.yahoo.com

ANALYSIS:

Without the $370,000 (one time) severace payment CIST would have made a profit!!!

Although sales reduced by 40%, License Fees and Funded Research more than offset that by increasing by 350%.

Earnings/Loss per share improved 100%


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News